(MBOT) Microbot Medical - Overview
Stock: Surgical Robot, Microcatheter Device, Anchoring System
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 99.7% |
| Relative Tail Risk | -19.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.17 |
| Alpha | -36.49 |
| Character TTM | |
|---|---|
| Beta | 1.617 |
| Beta Downside | 1.093 |
| Drawdowns 3y | |
|---|---|
| Max DD | 75.94% |
| CAGR/Max DD | -0.24 |
Description: MBOT Microbot Medical January 18, 2026
Microbot Medical Inc. (NASDAQ: MBOT) develops robotic platforms for endovascular interventions, most notably the LIBERTY system, which lets physicians operate catheters remotely to reduce radiation exposure, ergonomic strain, and cross-contamination risk across cardiovascular, peripheral, and neurovascular procedures.
In addition to LIBERTY, the firm owns the NovaCross technology-a revascularization device featuring an anchoring mechanism and integrated micro-catheter-positioning it within the broader intraluminal device market that is projected to grow at a CAGR of roughly 6% through 2028 (source: MarketResearch.com). As of Q3 2024, Microbot reported a cash runway of ~ 12 months and a pipeline of three FDA-cleared pre-clinical studies, reflecting the capital-intensive nature of regulatory milestones in this niche. The company’s collaborations with Corewell Health and Emory University aim to accelerate clinical adoption, but the timeline for widespread reimbursement remains uncertain given the evolving payer landscape for robotic surgery.
Given the high-growth trajectory of the robotic surgery sector and the company’s early-stage status, a quantitative deep-dive on ValueRay can help assess MBOT’s risk-adjusted upside.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -13.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.13 > 0.02 and ΔFCF/TA 158.8 > 1.0 |
| NWC/Revenue: 92.7k% < 20% (prev 2552 %; Δ 90.1k% < -1%) |
| CFO/TA -0.13 > 3% & CFO -11.0m > Net Income -13.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 27.53 > 1.5 & < 3 |
| Outstanding Shares: last quarter (48.1m) vs 12m ago 192.0% < -2% |
| Gross Margin: 25.0% > 18% (prev 0.30%; Δ 2470 % > 0.5%) |
| Asset Turnover: 0.19% > 50% (prev 2.73%; Δ -2.53% > 0%) |
| Interest Coverage Ratio: -32.12 > 6 (EBITDA TTM -13.4m / Interest Expense TTM -420.0k) |
Altman Z'' -15.00
| A: 0.95 (Total Current Assets 80.8m - Total Current Liabilities 2.93m) / Total Assets 81.8m |
| B: -1.23 (Retained Earnings -100.6m / Total Assets 81.8m) |
| C: -0.31 (EBIT TTM -13.5m / Avg Total Assets 43.5m) |
| D: -28.27 (Book Value of Equity -100.0m / Total Liabilities 3.54m) |
| Altman-Z'' Score: -29.53 = D |
What is the price of MBOT shares?
Over the past week, the price has changed by -2.22%, over one month by -17.37%, over three months by -13.30% and over the past year by -18.89%.
Is MBOT a buy, sell or hold?
- StrongBuy: 0
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the MBOT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 8.8 | 397.2% |
| Analysts Target Price | 8.8 | 397.2% |
| ValueRay Target Price | 1.6 | -11.4% |
MBOT Fundamental Data Overview February 03, 2026
P/B = 1.5454
Revenue TTM = 84.0k USD
EBIT TTM = -13.5m USD
EBITDA TTM = -13.4m USD
Long Term Debt = 899.0k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 297.0k USD (from shortTermDebt, last quarter)
Debt = 899.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -5.80m USD (from netDebt column, last quarter)
Enterprise Value = 41.6m USD (120.9m + Debt 899.0k - CCE 80.2m)
Interest Coverage Ratio = -32.12 (Ebit TTM -13.5m / Interest Expense TTM -420.0k)
EV/FCF = -3.78x (Enterprise Value 41.6m / FCF TTM -11.0m)
FCF Yield = -26.48% (FCF TTM -11.0m / Enterprise Value 41.6m)
FCF Margin = -13.1k% (FCF TTM -11.0m / Revenue TTM 84.0k)
Net Margin = -15.6k% (Net Income TTM -13.1m / Revenue TTM 84.0k)
Gross Margin = 25.0% ((Revenue TTM 84.0k - Cost of Revenue TTM 63.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 0.51 (Enterprise Value 41.6m / Total Assets 81.8m)
Interest Expense / Debt = 7.34% (Interest Expense 66.0k / Debt 899.0k)
Taxrate = 21.0% (US default 21%)
NOPAT = -10.7m (EBIT -13.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 27.53 (Total Current Assets 80.8m / Total Current Liabilities 2.93m)
Debt / Equity = 0.01 (Debt 899.0k / totalStockholderEquity, last quarter 78.2m)
Debt / EBITDA = 0.43 (negative EBITDA) (Net Debt -5.80m / EBITDA -13.4m)
Debt / FCF = 0.53 (negative FCF - burning cash) (Net Debt -5.80m / FCF TTM -11.0m)
Total Stockholder Equity = 35.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -30.06% (Net Income -13.1m / Total Assets 81.8m)
RoE = -37.06% (Net Income TTM -13.1m / Total Stockholder Equity 35.3m)
RoCE = -37.30% (EBIT -13.5m / Capital Employed (Equity 35.3m + L.T.Debt 899.0k))
RoIC = -30.22% (negative operating profit) (NOPAT -10.7m / Invested Capital 35.3m)
WACC = 11.83% (E(120.9m)/V(121.8m) * Re(11.87%) + D(899.0k)/V(121.8m) * Rd(7.34%) * (1-Tc(0.21)))
Discount Rate = 11.87% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 99.14%
Fair Price DCF = unknown (Cash Flow -11.0m)
EPS Correlation: 93.95 | EPS CAGR: 76.95% | SUE: 1.77 | # QB: 1
Revenue Correlation: 15.73 | Revenue CAGR: 0.0% | SUE: -4.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.08 | Chg30d=-0.030 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=-0.34 | Chg30d=-0.440 | Revisions Net=-1 | Growth EPS=-11.5% | Growth Revenue=+3119.3%